Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Anticonvulsants

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    80 result(s) found for: Anticonvulsants. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2007-000565-37 Sponsor Protocol Number: RD-5103-003-07 Start Date*: 2007-09-17
    Sponsor Name:University of Nottingham
    Full Title: A Prospective Study to Determine the Adverse Drug Reactions Profile of Anticonvulsants in Children
    Medical condition: Childhood epilepsy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015037 Epilepsy LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004201-26 Sponsor Protocol Number: NC200602 Start Date*: 2007-03-15
    Sponsor Name:Neuro-Consil GmbH
    Full Title: Efficacy and tolerability of flexible dose adjusted pregabalin as first-line add-on treatment of patients with focal seizures
    Medical condition: epilepsis with seizures of focal origin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001645-26 Sponsor Protocol Number: TMZ-FTM.CB.1 Start Date*: 2008-06-01
    Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA"
    Full Title: Phase II study: Systemic treatment with alternating weekly regimen of temozolomide and monthly fotemustine combination in recurrent glioblastoma patients.
    Medical condition: Glioblastoma recurrent
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018336 Glioblastoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-003905-15 Sponsor Protocol Number: GLITEM08 Start Date*: 2008-07-29
    Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA"
    Full Title: Carmustine implant (Gliadel Wafer) plus adjuvant and concomitant Temozolomide in combination with radiotherapy in primary glioblastoma patients.
    Medical condition: glioblastoma recurrent
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018336 Glioblastoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002625-11 Sponsor Protocol Number: MO29983 Start Date*: 2016-12-06
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: AN OPEN LABEL, SINGLE ARM, MULTICENTER, SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT
    Medical condition: Advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) EE (Completed) LT (Completed) DE (Completed) HU (Completed) IE (Completed) DK (Completed) CZ (Completed) PT (Completed) GB (GB - no longer in EU/EEA) BG (Completed) NL (Completed) PL (Completed) ES (Completed) BE (Completed) SK (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001890-15 Sponsor Protocol Number: SD-809-C-18 Start Date*: 2014-11-12
    Sponsor Name:Auspex Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA
    Medical condition: Tardive Dyskinesia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-003688-24 Sponsor Protocol Number: P12.??? Start Date*: 2012-12-12
    Sponsor Name:Leiden University Medical Center
    Full Title: Treatment of Complex Regional Pain Syndrome type 1: A randomized placebo controlled double-blind study with ARA 290
    Medical condition: Complex regional pain syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001168-55 Sponsor Protocol Number: TPU-EU FP-LBP-012007 Start Date*: 2008-03-14
    Sponsor Name:Teikoku Pharma USA, Inc.
    Full Title: A Multi Center Randomized, Double-Blind, Placebo-Controlled Trial of Flurbiprofen Patch for Treatment of Chronic Low Back Pain
    Medical condition: Chronic Low Back Pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000410-38 Sponsor Protocol Number: LP0066-1019 Start Date*: 2013-10-25
    Sponsor Name:LEO Pharma A/S
    Full Title: Topical Aprepitant in Prurigo Patients (iTAPP) An exploratory phase IIa trial with topically applied aprepitant in patients with prurigo
    Medical condition: Prurigo can present either with hyperkeratotic nodules as prurigo nodularis or without nodules as Prurigo simplex. The disease is characterised by intensely pruritic, lichenified, or excoriated pap...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002055-15 Sponsor Protocol Number: J81J1100168007 Start Date*: 2014-01-28
    Sponsor Name:UNIVERSITY OF SASSARI
    Full Title: RANDOMIZED, CONTROLLED, MULTI-CENTER, INTERNATIONAL CLINICAL STUDY ON THE MOOD-STABILIZING EFFECTS OF MEMANTINE AS AN AUGMENTING AGENT vs. LAMOTRIGINE FOR ONGOING TREATMENT IN BIPOLAR-I DISORDER P...
    Medical condition: BIPOLAR I MOOD DISORDERS
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003945-16 Sponsor Protocol Number: EGF105764 Start Date*: 2006-01-20
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: An open-label, single-arm, multicentre, Phase II study of oral lapatinib in combination with paclitaxel as first-line treatment for ErbB2-amplified metastatic breast cancer patients
    Medical condition: Metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2007-003372-18 Sponsor Protocol Number: NERI-AS001-07 Start Date*: 2007-12-03
    Sponsor Name:ABIOGEN PHARMA
    Full Title: A randomised, double-blind, placebo controlled study to assess the safety and the efficacy of neridronate 100 mg - 4 i.v. infusions in a course of 10 days treatment - in patients with algodystrophi...
    Medical condition: Algodystrophic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028395 Musculoskeletal and connective tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000846-35 Sponsor Protocol Number: EFG100161 Start Date*: 2005-09-07
    Sponsor Name:GlaxoSmithKline
    Full Title: GlaxoSmithKline Study EGF100161 – An open-label, multicenter, 2 Part, Phase I/II dose escalation study of oral lapatinib in combination with docetaxel (Taxotere) plus trastuzumab (Herceptin) in sub...
    Medical condition: Metastatic Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005326-23 Sponsor Protocol Number: PHRC-K2020PEZET Start Date*: 2022-01-24
    Sponsor Name:CHU de Clermont-Ferrand
    Full Title: Evaluation of the efficacy of donepezil in the treatment of oxaliplatin-induced peripheral neuropathy: proof of concept study
    Medical condition: Oxaliplatine-induced peripheral neuropathy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001685-35 Sponsor Protocol Number: ADT-2022-003 Start Date*: 2022-12-27
    Sponsor Name:Adeptio Pharmaceuticals Limited
    Full Title: Randomized, double-blind, placebo controlled clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia.
    Medical condition: Tardive dyskinesia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10043118 Tardive dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002909-10 Sponsor Protocol Number: P137 Start Date*: 2022-10-24
    Sponsor Name:Maastricht University
    Full Title: THE IMPACT OF PSILOCYBIN ON PAIN IN FIBROMYALGIA PATIENTS AND HEALTHY VOLUNTEERS: A MULTICENTER TRIAL
    Medical condition: Fibromyalgia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001284-27 Sponsor Protocol Number: ENHANCE Start Date*: 2022-09-07
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med I, Onkologie
    Full Title: H1-antihistaminE treatment in combiNation with immunotHerapy in pAtieNts with advanced non small cell lung canCEr: A single- center phase II trial
    Medical condition: NSCLC
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000245-13 Sponsor Protocol Number: SOLTI-1907 Start Date*: 2021-03-04
    Sponsor Name:SOLTI
    Full Title: A Phase II with 2 parallel cohorts clinical trial targeting estrogen receptor negative or PAM50 non-luminal disease with Atezolizumab in combination with Trastuzumab and Vinorelbine in HER2-positiv...
    Medical condition: Pre- and post-menopausal women with locally advanced or metastatic HER2-positive breast cancer who have progressed to trastuzumab/pertuzumab and T-DM1.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003926-24 Sponsor Protocol Number: EGF104900 Start Date*: 2006-01-30
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: A randomized, multicentre, open-label Phase III study of lapatinib in combination with trastuzumab versus lapatinib monotherapy in subjects with metastatic breast cancer whose disease has progresse...
    Medical condition: Metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) FI (Completed) HU (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Completed) GR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003207-30 Sponsor Protocol Number: GO29436 Start Date*: 2015-05-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN+PACLITAXEL WITH OR WITHOUT BEVACIZUMAB COMPARED WITH CARBOPLATIN+PACLITAXE...
    Medical condition: Stage IV non-squamous non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) AT (Completed) DE (Completed) BE (Completed) ES (Completed) BG (Completed) NL (Completed) LT (Completed) PT (Completed) FR (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 16:04:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA